Role of p27 in prostate carcinogenesis

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 337-344

  Macri, Ettore ^b   Loda, Massimo ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Belluno City Hospital   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cyclin dependent kinase inhibitors; p27; Prostate cancer

Indexed keywords

ANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEASOME; PROTEIN P27; UBIQUITIN;

AGGRESSION; ANIMAL CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL CYCLE S PHASE; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0001746766     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006133620914     Document Type: Review

References (70)

1. Sherr CJ: Cancer cell cycles. Science 274: 1672-7, 1996
2. Del Sal G, Loda M, Pagano M: Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog 7: 127-42, 1996
3. Kanib A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-40, 1994
4. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-59, 1997
5. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Develop 1998; 12: 2984-91
6. Levine M: p53, the cellular gatekeeper for growth and division. Cell 88: 323-31, 1997
7. Hatada I, Mukai T: Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11: 204-6, 1995
8. Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.AP Proc Natl Acad Sci USA 93: 3026-30, 1996
9. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387: 151-8, 1997
10. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague: p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. J Cancer Res 55: 1211-4, 1995
11. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. J Cell 78: 59-66, 1994
12. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin- Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994
13. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14: 3683-94, 1994
14. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent- kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325-31, 1996
15. Hershko A: Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9: 788-99, 1997
16. Goldberg AL: Functions of the proteasome: the lysis at the end of the tunnel. Science 268: 522-3, 1995
17. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-5, 1995
18. Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11: 1245-56, 1997
19. Gupta K, Copeland NG, Gilbert DJ, Jenkins NA, Gray DA: Unp, a mouse gene related to the tre oncogene. Oncogene 8: 2307-10, 1993
20. Gray DA, Inazawa J, Gupta K, Wong A, Ueda R, Takahashi T: Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. Oncogene 10: 2179-83, 1995
21. Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD: DUB-1, a deubiquitinating enzyme with growth- suppressing activity. Proc Natl Acad Sci USA 93: 3275-9, 1996
22. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464-78, 1997
23. Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J 11: 1067-75, 1997
24. Jackson PK: Cell cycle: cull and destroy. Curr Biol 6: 1209-12, 1996
25. Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim US: Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 36: 31-8, 1998
26. MacGrogan D, Bookstein R: Tumour suppressor genes in prostate cancer. Semin Cancer Biol 8: 11-9, 1997
27. Paul R, Ewing CM, Jarrard DF, Isaacs WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 79 (Suppl 1): 37-43, 1997
28. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 142: 557-71, 1998
29. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E: Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271: 499-502, 1996
30. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87: 1069-78, 1996
31. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-10, 1996
32. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133: 391-403, 1996
33. Shulze A, Zerfass-Thome K, Berges J, Middendorp S, Jansen-Durr P, Henglein B: Anchorage-dependent transcription of the cyclin A gene. Mol Cell Biol 16: 4632-8, 1996
34. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M: Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153: 681-7, 1998
35. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perimutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-44, 1996
36. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffinan ES, Ono M, Khanam D, Hayday AC, Frohinan LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-32, 1996
37. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-20, 1996
38. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-80, 1998
39. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML: Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 380: 262-5, 1996
40. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P: Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13: 2323-30, 1996
41. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995
42. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD: Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206-10, 1995
43. Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 56: 1413-7, 1996
44. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-4, 1996
45. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-63, 1997
46. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-30, 1997
47. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-5, 1997
48. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 3: 593, 1997
49. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-4, 1997
50. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-5, 1997
51. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58: 1730-5, 1998
52. Lloyd RV, Erikson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. P27kip1 a multifunctional cyclin- dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol (in press)
53. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542-8, 1998
54. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P: Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 11: 324-8, 1998
55. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKemion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-5, 1998
56. Cote RI, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916-20, 1998
57. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90: 1284-91, 1998
58. De Marzo AM, Meeker AK, Epstein JI, Coffey DS: Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153: 911-9, 1998
59. Guo Y, Sklar GN, Borkowski A, Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3: 2269-2274, 1997
60. Cunha GR, Donjacour A: Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 239: 251-72, 1987
61. van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH: The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40: 207-14, 1991
62. Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 1994; 49: 433-502
63. Leav I, Merk FB, Kwan PW, Ho SM: Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15: 23-40, 1989
64. Ho SM, Damassa D, Kwan PW, Seto HS, Leav I: Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. J Androl 6: 279-90, 1985
65. Leav I, Kwan PW, Merk FB, Chang C, Ho SM: Immunohistochemical and in situ hybridization studies of androgen receptor expression in a transplantable androgen- independent prostatic carcinoma line (MT) of Noble rats. Lab Invest 67: 788-95, 1992
66. Chen Y, Robles M, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ: Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7: 1571-8, 1996
67. Kokontis JM, Hay N, Liao S: Progression of LNCap prostate tumor cells during androgen deprivation: hormone- independent growth, repression of proliferation by androgen, and role lor p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-53, 1998
68. Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T: Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 411: 1-6, 1997
69. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15: 6595-604, 1996
70. Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-73, 1994